Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
Titel:
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
Auteur:
Uehara, Y. Takeyasu, Y. Yoshida, T. Tateishi, A. Torasawa, M. Hosomi, Y. Masuda, K. Shinno, Y. Matsumoto, Y. Okuma, Y. Goto, Y. Horinouchi, H. Yamamoto, N. Ohe, Y.